“Johnson & Johnson’s experimental coronavirus vaccine protected macaque monkeys with a single shot in a pre-clinical study, potentially gaining on other vaccines that are further along in testing but require two doses over time,” reports Bloomberg:
Five of six primates exposed to the pandemic-causing pathogen were immune after a single injection. The exception showed low levels of the virus, according to a study published in the medical journal Nature…
The health-care behemoth kick-started human trials on July 22 in Belgium and in the U.S. earlier this week. Although other vaccine-makers have moved more quickly into development, with AstraZeneca having already administered its experimental vaccine to almost 10,000 people in the U.K., gaining protection with a single dose could prove an advantage in the logistical challenge of rolling out massive vaccination programs worldwide…. The primate data show that the coronavirus vaccine candidate generated a strong antibody response, and provided protection with only a single dose, said Paul Stoffels, the drugmaker’s chief scientific officer.
J&J aims to embark on the last phase of tests in September, compressing the traditional timeline as it races against others including AstraZeneca, Moderna Inc., Pfizer Inc. and GlaxoSmithKline Plc for a shot to end the pandemic…. The New Brunswick, New Jersey-based drugmaker will test both a one-dose coronavirus shot, and a shot coupled with a booster in its early-stage studies of more than 1,000 adults, which launched this month.
Read more of this story at Slashdot.